Medicare Opens Coverage for Obesity Drugs

The initiative, known as the Bridge demonstration program, allows eligible beneficiaries to obtain prescription drugs for obesity with a $50 monthly copay. While Medicare Part D plans previously covered GLP-1s for diabetes or cardiovascular conditions, federal law historically prohibited coverage for weight loss alone. Officials at the Centers for Medicare and Medicaid Services estimate that several million people may utilize the program, though the rollout faces immediate logistical hurdles. Physicians must navigate a prior authorization process to confirm eligibility, a requirement that some clinicians fear will overwhelm busy medical practices and pharmacies.

Long-term access remains the primary concern for both patients and policy experts. The current program is scheduled to expire at the end of 2027, leaving a gap in coverage for individuals who require these treatments as lifelong therapies. Juliette Cubanski of KFF noted that while the expansion is a positive development, the lack of a permanent legislative solution creates significant uncertainty. Without future action from the federal government or changes to private insurer policies, patients beginning these treatments now face the prospect of losing access once the 18-month demonstration concludes.